Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Completed · Phase 1
Conditions studied: Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
In brief
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving bortezomib together with cetuximab may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when given together with cetuximab in treating patients with advanced solid tumors.
Key facts
- Study ID
- NCT00622674
- Run by
- Masonic Cancer Center, University of Minnesota
- People needed
- 37
- Starts
- 2005-11-01
- Expected to finish
- 2010-02-01
- Last updated by the study team
- 2017-12-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of solid tumor that overexpresses epidermal growth factor receptor (EGFR) including, but not limited to, the following:
- Breast cancer
- Lung cancer
- Colon cancer
- Pancreatic cancer
- Head and neck cancer
- Kidney cancer
- Sarcoma
- Advanced disease
- Must have failed or become intolerant to prior standard therapy and is no longer likely to respond to such therapy
- Measurable or nonmeasurable disease
- ECOG performance status 0-1
- ANC ≥ 1,500/mm³
- Platelet count > 100,000/mm³
- Hemoglobin > 9 g/dL
- Bilirubin < 1.5 times upper limit of normal (ULN)
- Alkaline phosphatase < 3.0 times ULN (5.0 times ULN if liver has tumor involvement)
- Aspartate aminotransferase (AST) and alanine aminotransferase (*ALT) < 3.0 times upper limit of normal (ULN) (5.0 times ULN if liver has tumor involvement)
- Creatinine clearance > 30 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after completion of study treatment
- Recovered from all prior therapy
- Prior systemic chemotherapy, immunotherapy, or biological therapy allowed
- At least 14 days since prior radiotherapy or systemic therapy
You may not qualify if…
- Untreated or symptomatic central nervous system (CNS) metastases
- Concurrent serious systemic disorders (e.g., active infection) that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study
- Uncontrolled diabetes
- Myocardial infarction within the past 6 months
- New York Heart Association (NYHA) class III or IV heart failure
- Uncontrolled angina
- Severe uncontrolled ventricular arrhythmias
- Evidence of acute ischemia or active conduction system abnormalities by ECG
- Peripheral neuropathy Common Terminology Criteria for Adverse Events (CTCAE) grade > 2
- Known hypersensitivity to bortezomib, boron, or mannitol
- Serious medical or psychiatric illness likely to interfere with study participation
- Prior bortezomib and/or cetuximab
- Concurrent filgrastim (G-CSF) or other hematologic support during course 1 of study treatment
Where it is running
- Masonic Cancer Center at University of Minnesota — Minneapolis, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.